Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101

NCT02122952 is registered in ClinicalTrials.gov with Novartis Gene Therapies as lead sponsor.

NCT NCT02122952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02122952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101
Lead sponsor
Novartis Gene Therapies
Phase
Phase 1
Overall status
Completed
Start date
May 5, 2014
Completion date
December 15, 2017
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy 1